NASDAQ:ORPN Bioblast Pharma (ORPN) Stock Price, News & Analysis → Global crypto currency reset (41 major banks signed up) (From Stansberry Research) (Ad) Free ORPN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.24▼$1.3050-Day Range$11.50▼$28.4952-Week Range$6.16▼$30.00Volume51,407 shsAverage VolumeN/AMarket Capitalization$533,400.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsSocial MediaStock AnalysisCompetitorsSocial Media Get Bioblast Pharma alerts: Email Address Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. About Bioblast Pharma Stock (NASDAQ:ORPN)Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, Graft-versus-Host disease resulting from bone-marrow transplantations, solid organ transplantations and an assembly of autoimmune and inflammatory conditions, such as Crohn's disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders. The company is headquartered in Nes-Ziona, Israel.Read More Ad Stansberry ResearchGlobal crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know. ORPN Stock News HeadlinesApril 10, 2024 | markets.businessinsider.comEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaMarch 14, 2024 | barrons.comAnaptysBio Inc.April 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...February 23, 2024 | msn.comWhat's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?February 23, 2024 | morningstar.comLantern Pharma Inc Ordinary Shares LTRNFebruary 18, 2024 | msn.comQBiotics wins FDA orphan status for rainforest-derived cancer drugFebruary 18, 2024 | seekingalpha.comPBSV Pharma-Bio Serv, Inc.February 5, 2024 | markets.businessinsider.comAnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic SclerosisApril 23, 2024 | Stansberry Research (Ad)Global crypto currency reset (41 major banks signed up)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...January 4, 2024 | markets.businessinsider.comLumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerNovember 3, 2023 | marketwatch.comPlus Therapeutics Shares Jump Premarket on FDA Orphan DesignationMarch 31, 2023 | wsj.comChangzhou Qianhong Bio-Pharma Co. Ltd. AMarch 1, 2023 | marketwatch.com2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for DevelopmentFebruary 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028February 15, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028February 13, 2023 | thestreet.comBioBlast Scant Data Links Drug to Improved Swallowing in PatientsJanuary 30, 2023 | seekingalpha.comBioMarin: Opportunity To Score Home Run With Latest Regulatory AdvancementsJanuary 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028October 16, 2022 | finance.yahoo.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027September 21, 2022 | seekingalpha.comENLV Enlivex Therapeutics Ltd.August 31, 2022 | marketwatch.comBioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans ProgressivaAugust 31, 2022 | msn.comBioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease CandidateAugust 12, 2022 | finance.yahoo.comAro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe DiseaseAugust 11, 2022 | seekingalpha.comBioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call TranscriptAugust 1, 2022 | finance.yahoo.comBiosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic SyndromesJuly 12, 2022 | markets.businessinsider.comCitius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell LymphomaJuly 8, 2022 | apnews.comGlobal Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.comSee More Headlines Receive ORPN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioblast Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ORPN CUSIPN/A CIK1596812 Webbioblastpharma.com Phone(722) 670-8072FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.56 per share Price / Book0.17Miscellaneous Outstanding Shares420,000Free FloatN/AMarket Cap$533,400.00 OptionableNot Optionable Beta1.41 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesOren HershkovitzChief Executive OfficerShachar ShlosbergerChief Financial OfficerDror MevorachChief Scientific & Medical OfficerOdelia Ben-ShitritHead-Clinical OperationsKey CompetitorsAditxtNASDAQ:ADTXBellerophon TherapeuticsNASDAQ:BLPHAllarity TherapeuticsNASDAQ:ALLRChina SXT PharmaceuticalsNASDAQ:SXTCEvofem BiosciencesNASDAQ:EVFMView All Competitors ORPN Stock Analysis - Frequently Asked Questions When did Bioblast Pharma's stock split? Bioblast Pharma's stock reverse split on the morning of Wednesday, March 6th 2019. The 1-8 reverse split was announced on Wednesday, March 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 5th 2019. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Bioblast Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioblast Pharma investors own include Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Immunomedics (IMMU), Verastem (VSTM), Voyager Therapeutics (VYGR), Athersys (ATHX), ContraFect (CFRX), CTI BioPharma (CTIC) and Eleven Biotherapeutics (EBIO). This page (NASDAQ:ORPN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishingtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
